February 17, 2014
CASE CCC IN THE NEWS
Crowdsourced Testers Prefer New Cyber Search Method Created by CWRU Computer Scientists
FDA Approves New Leukemia Drug; May One Day Make Chemo Obsolete for Some CLL Patients
Biologics Showing Great Promise for Breast Cancer Treatment
Poor Sleep Causes Premature Skin Aging
Multiple Myeloma: 'Incurable, But Highly Treatable'
Tom Brokaw's Multiple Myeloma Diagnosis Spotlights Incurable Cancer
Oncology: Colorectal Cancer (video)
Cancer Risk Spurs Concern Over Gyn Procedure
For Younger Women, Study Reveals Mammography Saves Live
MicroRNA-181a Shows Promise as a Biomarker for Late-Stage Ovarian Cancer
Annoyed When e-cigarette Users 'Light Up' Near You? It Depends on Where You Are, New Survey Says
Distelhorst Lab Discovers Pathway of Protein that Helps Cancer Cells Survive
A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer. The breakthrough emerged when the scientists discovered that Bcl-2 alters the level of calcium ions in lymphoma and leukemia cells that are resistant to cancer treatments. Published in the journal Proceedings of the National Academy of Sciences (PNAS), the research findings could help lead to the development of drugs that attack Bcl-2 in malignancies and produce better outcomes for cancer treatment.
"One of the deadliest and most remarkable characteristics of cancer cells is that regardless of where they are growing, and no matter what types of treatments are employed, including many different forms of chemotherapy and radiation therapy, the cancer cells have the ability to survive," said Clark W. Distelhorst, MD, Professor, Medicine-Hematology/Oncology, Pharmacology, Case Western Reserve School of Medicine. "Since 1993 our team has been conducting research on key mechanisms by which the protein Bcl-2 keeps cancer cells alive."
Disease Team sign-off and PRMC protocol submission
Effective immediately, the Protocol Review and Monitoring Committee (PRMC) will not be accepting protocol submissions without Disease Team sign-offs from both institutions. One of the functions of the Case CCC Clinical Trials Disease Teams is to "recommend action to PRMC for trial advocacy and priority" by providing "pre-review by experts in their field for scientific merit, prioritization, and intent to accrue patients" (Case CCC Clinical Trials Operations Manual).
Disease Team sign-off from both hospitals has been a long-standing requirement and protocol submissions will no longer be accepted by PRMC without it. Please note that the overall responsibility of following-up and obtaining sign-offs rests with the PI and the study team. Contact April Firstencel, PRMC Manager, at 216.286.2294 or firstname.lastname@example.org with any questions.
SAVE THE DATE
Team Science Workshop
On Monday, February 17 the Clinical and Translational Science Collaborative (CTSC) will host a Team Science Workshop from 1-4 pm in the Wolstein Research Building Auditorium. This workshop is a forum to enhance our understanding of Team Science and how it can advance research efforts through collaboration. Team Science is a collaborative and multidisciplinary research effort that joins together researchers to explore a specific research problem with specific targeted goals. Team Science collaborations can join together individuals from the same department, other institutions, community organizations, and/or other organizations that typically do not interact with one another. Teams can vary in focus from training, clinical translation, public health issues, and scientific discovery.
The National Institutes of Health has been explicit in its support of Scientists working in teams to solve complex problems. The National Center for the Advancement of Translational Sciences promotes this model. The partner institutions will demonstrate their support of a team science environment by enhancing the infrastructure through pilot funding, technology transfer resources and support, and other shared resources.
Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar
The Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar, will be held on February 26 at 4pm in the Global Cardiovascular Innovation Center, 10000 Cedar Avenue. This first seminar will feature a presentation by Dr. Goutham Narla, Assistant Professor, Medicine and Transformative Molecular Medicine at CWRU/UH, on Drugging the Undruggable: Small Molecule Activators of Tumor Suppressor Genes.
As part of the Case CCC Developmental Therapeutics Program, this series will gather clinicians, scientists, medical chemists, computer-aided drug designers, screeners, and commercialization personnel in the same room as a stimulating presentation so that all attendees can learn and benefit from the sparked interaction.
Retreat: Engaging in Cultural Competence through Awareness, Knowledge and Action
Please mark your calendars for Thursday, March 13 from 2-5 pm to join the Case Comprehensive Cancer Center and the Case Center for Reducing Health Disparities as they explore issues related to cultural competence. Extend your knowledge and raise your awareness about the dynamic variety of people and communities the Case CCC serves. This retreat will feature a keynote address by Dr. Sonja Harris-Haywood, and will provide perspective on the growing need to be culturally competent and facilitate the impact of cultural beliefs within the health care setting, specifically in research.
The retreat is intended for investigators, research nurses, regulatory coordinators, outreach and training and education personnel. Pre-registration is required. Please direct any questions to Katarzyna Karelus at 216.844.4176 or email@example.com.
Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant
The American Association for Cancer Research (AACR), on behalf of Stand Up To Cancer (SU2C) and the Dutch Cancer Society - KWF Kankerbesrtijding (KWF), is accepting applications for a Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant that will offer up to €6 million in research funding. The grant provides four years of funding for a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional team of expert investigators. Research projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic agents to the clinic, and may focus on particular organ sites or on specialized research areas.
Alex's Lemonade Stand Foundation
Alex's Lemonade Stand Foundation (ALSF) is accepting applications for the following funding opportunities:
Genetics Student Seminar
Pathology Research Seminar Series
Genomic Medicine Institute Seminar Series
Radiation Oncology Grand Rounds
Molecular Genetics Departmental Seminar
Immunology Seminar Series
Hematology and Oncology Division Research Conference
Pathology Faculty Candidate
Genetics and Genome Sciences Seminar
Cancer Trainee Seminar
Genetics and Genome Sciences Journal Club
Immunology Journal Club
Molecular Biology and Microbiology Seminar
Hematology/Oncology Fellows Conference/Curriculum Series
Taussig Cancer Institute Grand Rounds
Cellular and Molecular Medicine Seminar Series
Cancer Center Seminar Series, co-sponsored by the Dept. of Genetics and Genome Sciences
Cancer Center Research in Progress
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Screening for Cancer in Women: 2014
Case CCC Annual Scientific Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS
International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery
1st Annual Multidisciplinary Colorectal Oncology Course
PREVIOUSLY ANNOUNCED OPPORTUNITIES
ASH HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award
American Cancer Society RFA: The Role of Healthcare and Insurance in Improving Outcomes in Cancer Prevention, Early Detection and Treatment
NIH BULLETIN – Notices and Funding Opportunities
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44)(RFA-CA-14-002)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.
Connect with Us